Clinical Trials Directory

Trials / Completed

CompletedNCT03085654

Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
147 (actual)
Sponsor
University of Electronic Science and Technology of China · Academic / Other
Sex
Male
Age
18 Years – 30 Years
Healthy volunteers
Accepted

Summary

To examine whether multiple doses of oxytocin have different effects on behavior and neural indices in males with high or low trait anxiety.

Detailed description

In the present study, healthy male subjects' trait anxiety levels will be assessed by the sub-trait inventory of the State-Trait Anxiety Inventory (STAI). According to subjects' trait anxiety scores, they will be divided into high or low anxiety experimental groups. Next, experiments will investigate the acute effect (single dose) and chronic effect (3 doses or 5 doses) of oxytocin on brain functional connectivity during resting-state and brain activation in response to watching emotional stimuli using functional magnetic resonance imaging (fMRI). Also the brain structure data (T1 and diffusion tensor imaging, DTI) of subjects will be collected. After finishing the scanning tasks, subjects will be required to rate the emotional valence, intensity and arousal of the pictures shown in the scanner. During the course of the study subjects will complete a number of questionnaires: Empathy Quotient (EQ), Cheek and Buss Shyness scale (CBSS),Interpersonal Reactivity Index (IRI),Childhood Trauma Questionnaire (CTQ),Beck depression inventory (BDI), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Liebowitz Social Anxiety Scale (LSAS),Positive and Negative Affect Schedule (PANAS),d2 attention test, and the Visual Analogue Scale for anxiety.

Conditions

Interventions

TypeNameDescription
DRUGOxytocin nasal sprayIntranasal administration of oxytocin 24 international units per dose.
DRUGPlacebo nasal sprayIntranasal administration of placebo 24 international units per dose.

Timeline

Start date
2017-03-03
Primary completion
2018-03-31
Completion
2018-04-30
First posted
2017-03-21
Last updated
2018-10-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03085654. Inclusion in this directory is not an endorsement.